MK-677 (Ibutamoren) – Research Compound Profile

MK-677 (Ibutamoren) – Research Compound Profile

Category: Hormonal Research | Molecular Type: Non-peptide growth hormone secretagogue | Research Status: Phase II Clinical Trials

This page compiles published research data for qualified researchers. MK-677 (Ibutamoren) is sold exclusively as a research compound and is not approved for human use.

Purchase for Research →

Molecular Overview

MK-677, also designated ibutamoren mesylate and originally developed as L-163,191, is a potent, orally bioavailable, non-peptide agonist of the growth hormone secretagogue receptor (GHS-R1a). It was first described by Patchett et al. (1995) as a peptidomimetic compound designed to stimulate endogenous pulsatile growth hormone (GH) secretion while maintaining oral activity — a critical distinction from peptide-based GH secretagogues such as GHRP-2, GHRP-6, and ipamorelin, which are not orally active [2, 9, 10].

As a non-peptide peptidomimetic, MK-677 is chemically unrelated to the secretagogue peptides it functionally mimics. Its scaffold is a spiropiperidine, supplied as the mesylate salt to improve crystallinity and aqueous solubility. Because it lacks a peptide backbone it is not a peptidase substrate, and this — rather than any difference in receptor pharmacology — is the structural basis for both its oral activity and its greater chemical robustness in storage. Biological activity resides in a single stereochemical configuration, so stereochemical purity is a meaningful specification for research material.

MK-677 functions as a ghrelin mimetic, binding the same receptor as the endogenous hunger hormone ghrelin, and has been studied extensively in Phase II clinical trials for its effects on the GH/IGF-1 axis, body composition, bone metabolism, and sleep architecture. The compound has been investigated across diverse populations including healthy elderly adults, obese males, calorie-restricted subjects, post-menopausal osteoporotic women, hip fracture patients, and Alzheimer’s disease patients [1, 3, 4, 5, 7, 8, 16].

MK-677 remains classified as an Investigational New Drug (IND) and has not received FDA approval for any clinical indication. It is listed as a prohibited substance by the World Anti-Doping Agency (WADA) [11].

Mechanism of Action

MK-677 exerts its primary effects through agonism of the growth hormone secretagogue receptor (GHS-R1a), the endogenous ligand of which is ghrelin [2, 10]. GHS-R1a is a class A G protein-coupled receptor coupling principally to Gα_q/11: agonist binding activates phospholipase C, mobilising intracellular calcium and activating protein kinase C. This pathway is distinct from the Gα_s/cyclic-AMP signalling of the GHRH receptor on the same somatotroph cells, which is why the two systems act synergistically rather than redundantly on GH exocytosis. GHS-R1a is also notable for high constitutive activity, which complicates interpretation of agonist potency data from recombinant expression systems. Unlike exogenous GH administration, which produces a single supraphysiological spike in circulating GH, MK-677 amplifies the endogenous pulsatile GH release pattern. Deconvolution analysis of 24-hour blood sampling in the Nass et al. (2008) trial confirmed that MK-677 primarily increased the amplitude of GH secretory pulses rather than their frequency, thereby maintaining a physiological secretory rhythm [1]. This enhanced pulsatile pattern produced statistically significant increases in mean 24-hour GH concentration and in the total pulsatile production rate relative to placebo at the 12-month assessment.

When MK-677 binds GHS-R1a on somatotroph cells in the anterior pituitary, it triggers intracellular calcium signaling and promotes GH exocytosis. Simultaneously, MK-677 appears to activate GHS-R1a at the hypothalamic level, stimulating the release of growth hormone-releasing hormone (GHRH) while potentially suppressing somatostatin tone [2, 10]. This dual action — both pituitary-direct and hypothalamic-mediated — underpins its robust and sustained GH-elevating effects. The resulting rise in IGF-1 engages a negative feedback loop that prevents unchecked GH production, a physiological safeguard that exogenous GH administration bypasses entirely [1].

Beyond the GH axis, MK-677’s ghrelin-mimetic activity produces several characteristic secondary effects documented in the literature. Ghrelin receptor activation in the arcuate nucleus stimulates appetite via neuropeptide Y (NPY) and agouti-related peptide (AgRP) pathways, accounting for the transient increase in appetite reported in clinical trials [1, 12]. MK-677 also promotes adipogenesis through ghrelin-mediated pathways distinct from the lipolytic actions of GH itself — creating a dual effect where subjects in the Nass et al. trial gained both lean mass and some peripheral fat [1]. Additionally, ghrelin receptor signaling in the suprachiasmatic nucleus and other sleep-regulatory centers is the proposed explanation for the changes in sleep architecture (increases in REM and stage IV slow-wave sleep) documented by Copinschi et al. (1997) [6].

Pharmacokinetics

MK-677 is rapidly absorbed, reaching peak plasma concentration (Tmax) within approximately 1 hour [9]. The compound’s plasma elimination half-life is approximately 4–6 hours as measured in beagle models, though its pharmacodynamic effects are considerably more sustained than that figure implies [2, 9]. A single exposure was observed to elevate circulating IGF-1 across a full 24-hour window [2, 3]. In the Chapman et al. (1996) study of elderly subjects, four weeks of exposure produced statistically significant increases in mean 24-hour GH concentration relative to baseline, with IGF-1 rising into the young-adult reference range within 2 weeks [3]. The compound did not appear to accumulate significantly with repeated exposure, and IGF-1 returned to baseline within 1 month of withdrawal, as confirmed by the Nass et al. crossover data [1].

Published Research Parameters

The following table indexes the study models, durations, and reported observations of selected peer-reviewed publications. Dose, frequency, and administration-route details are deliberately omitted. This is a bibliographic index only — not a protocol and not a recommendation for any use.

Stability & Storage Characteristics

Published literature and standard pharmaceutical handling practices indicate the following stability characteristics for MK-677:

• Form: MK-677 (ibutamoren mesylate) is typically supplied as a solid oral formulation or in solution. As a non-peptide small molecule, it exhibits greater inherent stability than lyophilized peptide compounds and does not require reconstitution with bacteriostatic water.
• Temperature: Standard storage conditions reported across clinical trials were controlled room temperature (15–25 °C / 59–77 °F). Unlike lyophilized peptides, refrigeration is not required for solid formulations.
• Moisture and light sensitivity: As with most small-molecule pharmaceutical compounds, MK-677 formulations should be protected from excessive moisture and direct light exposure to prevent degradation.
• Shelf life: Stability is formulation-dependent. Researchers should follow manufacturer-specified expiration dating for their specific product.
• Solution behaviour: Unlike lyophilized peptides, the compound is not aggregation-prone and is unaffected by freeze-thaw or mechanical agitation, so the practical stability concerns are hydrolytic and oxidative rather than physical.

Analytical Characterization

Because MK-677 is a small molecule rather than a peptide, its analytical panel differs from that used for peptide compounds. Reverse-phase HPLC with UV detection provides the primary purity measure and resolves synthetic intermediates and hydrolysis products. LC-MS confirms the molecular ion and its expected fragmentation pattern. Nuclear magnetic resonance is the definitive structural confirmation for this class and distinguishes the intended regiochemistry from synthetic isomers, which are indistinguishable from the parent by mass alone. Chiral chromatography confirms enantiomeric purity. Counter-ion content should be determined so that stated mass can be converted to free-base equivalent, and residual solvent testing is standard for synthetic small molecules.

Key Published Research Findings

GH/IGF-1 Axis Biomarkers

In the 2-year randomized, double-blind, placebo-controlled trial by Nass et al. (2008) published in Annals of Internal Medicine, MK-677 in healthy elderly adults (n=65) produced statistically significant increases in 24-hour mean GH and in serum IGF-1 relative to placebo, and a significant proportion of participants reached the young-adult IGF-1 reference range. These biomarker elevations were sustained across the full 2-year observation period without evidence of tachyphylaxis [1].

Body Composition Changes

In the same Nass et al. (2008) trial, fat-free mass differed significantly between the MK-677 and placebo arms at 12 months, with the direction of change opposite in the two groups — a divergence the authors interpreted as attenuation of age-related lean-mass loss [1]. Separately, Svensson et al. (1998) reported in the Journal of Clinical Endocrinology & Metabolism that two months of exposure in obese males produced statistically significant increases in fat-free mass and in 24-hour energy expenditure, without significant change in abdominal visceral fat [8].

Anti-Catabolic Effects During Caloric Restriction

Murphy et al. (1998), published in the Journal of Clinical Endocrinology & Metabolism, reported that MK-677 exposure significantly improved the negative nitrogen balance induced by caloric restriction in healthy adults relative to placebo, a finding the authors interpreted as evidence of anti-catabolic activity during energy-deficit states [4].

Bone Metabolism

Murphy et al. (1999), published in the Journal of Bone and Mineral Research, reported statistically significant increases in osteocalcin, a bone-formation marker, at 12 months in elderly adults, accompanied by significant increases in IGF-1 [5]. In a subsequent study, Murphy et al. (2001) examined MK-677 in combination with alendronate in post-menopausal osteoporotic women and observed additive changes in bone turnover markers, which the authors read as evidence of non-overlapping mechanisms between GH secretagogues and bisphosphonates at the level of bone remodelling biology [7]. Svensson et al. (1998) also reported increases in markers of bone formation and bone resorption in obese young males treated with MK-677 [12].

Sleep Architecture

Copinschi et al. (1997), published in Neuroendocrinology, reported that MK-677 exposure produced statistically significant increases in REM sleep in both young and elderly subjects, and a significant increase in slow-wave (stage IV) sleep in young subjects, as measured by polysomnography [6].

Lipid Profile

In the Nass et al. (2008) trial, LDL cholesterol differed significantly between the MK-677 and placebo arms over 12 months, one of several prespecified metabolic laboratory endpoints collected in that study [1].

Negative Clinical Findings

Sevigny et al. (2009), published in Neurology, conducted a randomized trial in Alzheimer’s disease patients and found no effect on the disease-progression endpoints assessed, despite achieving the expected GH/IGF-1 biomarker elevations. This dissociation between biomarker response and clinical endpoint is an important limitation on inference from the GH/IGF-1 data cited elsewhere on this page [16].

Safety Profile in Published Literature

Adverse Events Reported in Clinical Trials

The most comprehensive safety data come from the Nass et al. (2008) 2-year trial [1]:

• Appetite increase: Reported considerably more often in MK-677-treated subjects than in placebo. The effect subsided within the first few months in a substantial proportion of affected subjects [1].
• Lower-extremity edema: Reported more often in MK-677 subjects than in placebo, and generally described as transient and mild [1].
• Transient muscle pain: Reported more often in MK-677 subjects than in placebo, and resolved without intervention [1].
• Elevated fasting glucose: A small but statistically significant increase in fasting glucose, accompanied by a significant increase in HbA1c, was observed at 12 months. This is the safety signal most consistently reported across the MK-677 literature [1].
• Decreased insulin sensitivity: The Quicki Index declined significantly (P<0.001), indicating reduced insulin sensitivity. This was particularly relevant in subjects with pre-existing metabolic risk factors [1].
• Modest cortisol increase: Serum cortisol increased significantly at 12 months while remaining within the physiological reference range [1].

Mechanistic Considerations

MK-677 does not bind to androgen receptors and is mechanistically distinct from anabolic steroids and selective androgen receptor modulators (SARMs). Its pharmacological activity is mediated exclusively through ghrelin receptor agonism and downstream GH/IGF-1 axis stimulation [2, 10]. Sigalos et al. (2023) reviewed the published literature on GH secretagogues, including MK-677, in the context of age-related muscle loss, and noted the substantial limitations of the current evidence base [13]. Smith et al. (2007) discussed ghrelin receptor agonists in the biology of aging and highlighted the absence of long-term safety data [14].

Special Research Populations Studied

MK-677 has been investigated across diverse research populations, each yielding distinct findings:

• Healthy elderly adults (60–81 years): The Nass et al. (2008) 2-year trial reported sustained GH/IGF-1 biomarker elevation and a significant difference in fat-free mass, but no significant difference in strength or functional outcome measures in this already-healthy cohort [1].
• Obese males: Svensson et al. (1998) observed that two months of exposure produced statistically significant increases in GH secretion, fat-free mass, and 24-hour energy expenditure, without significant change in abdominal visceral fat [8].
• Diet-induced catabolic state: Murphy et al. (1998) reported that MK-677 exposure significantly improved the negative nitrogen balance caused by caloric restriction [4].
• Post-menopausal osteoporotic women: Murphy et al. (2001) studied MK-677 in combination with alendronate and reported additive changes in bone turnover markers [7].
• Hip fracture patients: A randomized trial of 123 elderly hip fracture patients assessed functional recovery endpoints, though interpretation was limited by the high dropout rate common in this frail population [16].
• Alzheimer’s disease patients: Sevigny et al. (2009) conducted a randomized trial and found no effect on the disease-progression endpoints assessed, despite achieving the expected GH/IGF-1 biomarker elevations [16].

Regulatory Status

• FDA Status: MK-677 (ibutamoren) is not FDA-approved for any clinical indication. It remains classified as an Investigational New Drug (IND).
• Clinical Trial Status: Phase II clinical trials have been conducted across multiple indications including age-related sarcopenia, obesity, osteoporosis, hip fracture recovery, and Alzheimer’s disease. No Phase III pivotal trials have been completed to date.
• WADA Status: MK-677 is classified as a prohibited substance by the World Anti-Doping Agency (WADA) under the category of growth hormone secretagogues [11].
• Research Use: This compound is sold exclusively for research purposes and is not intended for human consumption, athletic performance enhancement, or any clinical application.

Research Use Only

All information on this page is provided for informational and citation purposes and summarizes findings from published scientific literature. MK-677 (ibutamoren mesylate) supplied by IronPeak Peptides LLC is intended for laboratory research purposes only. It is not a drug, food, or cosmetic, is not intended for human or veterinary consumption, and is not intended to diagnose, treat, cure, or prevent any disease. Nothing on this page constitutes medical advice or a recommendation for use in humans. Handling should be performed only by qualified researchers in an appropriate laboratory setting.

References

1. Annals of Internal Medicine (2008) — Nass R, Pezzoli SS, Oliveri MC, et al. “Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial.” Ann Intern Med. 149(9):601–611. View Source

2. Endocrine Reviews (1997) — Smith RG, Van der Ploeg LH, Howard AD, et al. “Peptidomimetic regulation of growth hormone secretion.” Endocr Rev. 18(5):621–645. View Source

3. Journal of Clinical Endocrinology & Metabolism (1996) — Chapman IM, Bach MA, Van Cauter E, et al. “Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects.” J Clin Endocrinol Metab. 81(12):4249–4257. View Source

4. Journal of Clinical Endocrinology & Metabolism (1998) — Murphy MG, Plunkett LM, Gertz BJ, et al. “MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism.” J Clin Endocrinol Metab. 83(2):320–325. View Source

5. Journal of Bone and Mineral Research (1999) — Murphy MG, Bach MA, Plotkin D, et al. “Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults.” J Bone Miner Res. 14(7):1182–1188. View Source

6. Neuroendocrinology (1997) — Copinschi G, Leproult R, Van Onderbergen A, et al. “Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man.” Neuroendocrinology. 66(4):278–286. View Source

7. Journal of Clinical Endocrinology & Metabolism (2001) — Murphy MG, Weiss S, McClung M, et al. “Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.” J Clin Endocrinol Metab. 86(3):1116–1125. View Source

8. Journal of Clinical Endocrinology & Metabolism (1998) — Svensson J, Lönn L, Jansson JO, et al. “Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677: increases GH secretion, fat-free mass, and energy expenditure.” J Clin Endocrinol Metab. 83(2):362–369. View Source

9. PNAS (1995) — Patchett AA, Nargund RP, Tata JR, et al. “Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue.” Proc Natl Acad Sci USA. 92(15):7001–7005. View Source

10. Journal of Clinical Endocrinology & Metabolism (1997) — Chapman IM, Pescovitz OH, Murphy G, et al. “Oral administration of growth hormone (GH) releasing peptide-mimetic MK-677 stimulates the GH/insulin-like growth factor-I axis in selected GH-deficient adults.” J Clin Endocrinol Metab. 82(10):3455–3463. View Source

11. Sport Integrity Australia (2022) — “Ibutamoren (MK-677) not OK — Don’t be fooled by marketing!” WADA Prohibited List Classification. View Source

12. Journal of Bone and Mineral Research (1998) — Svensson J, Ohlsson C, Jansson JO, et al. “Treatment with the oral growth hormone secretagogue MK-677 increases markers of bone formation and bone resorption in obese young males.” J Bone Miner Res. 13(7):1158–1166. View Source

13. Journals of Gerontology Series A (2023) — Sigalos JT, Gittelman M, Engelen MPKJ, et al. “Growth hormone secretagogues as potential therapeutic agents to treat age-related muscle wasting.” J Gerontol A Biol Sci Med Sci. 78(Suppl 1):38–46. View Source

14. Annals of the New York Academy of Sciences (2007) — Smith RG, Sun Y, Jiang H, et al. “Ghrelin receptor (GHS-R1A) agonists show potential as interventive agents during aging.” Ann N Y Acad Sci. 1119(1):147–164. View Source

15. Journal of Clinical Endocrinology & Metabolism (1998) — Murphy MG, Bach MA, Plotkin D, et al. “Treatment of obese subjects with the oral growth hormone secretagogue MK-677: effects on lipoproteins.” J Clin Endocrinol Metab. 84(11):4016–4024. View Source

16. Neurology (2009) — Sevigny JJ, Ryan JM, van Dyck CH, et al. “Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial.” Neurology. 71(21):1702–1708. View Source

⚠️ Disclaimer: This page is provided for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. MK-677 (Ibutamoren) is sold exclusively as a research compound, has not been approved by the FDA for any use, and is not intended for human consumption or self-administration. All information is derived from published peer-reviewed literature. Research must comply with all applicable laws, regulations, and institutional guidelines.

Purchase MK-677 (Ibutamoren) for Research →